Zastosowanie nowoczesnych leków przeciwkrzepliwych w kardiologii

Thromboembolic complications in patients with atrial fibrillation (AF) are one of the leading problems in everyday clinical practice. The appropriate prophylaxis allows not only to reduce the incidence of ischemic strokes, but also to reduce mortality in this group of patients. New non-vitamin K antagonist oral anticoagulants, due to their high efficiency and favourable safety profile, are currently the standard of therapy in patients with AF and high thromboembolic risk. The choice of anticoagulant and its dose are based on the individual needs of the patient, adjusted to the renal function, the risk of bleeding, as well as the age and weight.